×
News Home

Where Does Halozyme Therapeutics, Inc. (HALO) Stock Fall in the Biotechnology Field After It Is Lower By -0.95% This Week?

Monday, October 04, 2021 02:59 PM | InvestorsObserver Analysts
Where Does Halozyme Therapeutics, Inc. (HALO) Stock Fall in the Biotechnology Field After It Is Lower By -0.95% This Week?

Halozyme Therapeutics, Inc. (HALO) is near the middle in its industry group according to InvestorsObserver. HALO gets an overall rating of 40. That means it scores higher than 40 percent of stocks. Halozyme Therapeutics, Inc. gets a 51 rank in the Biotechnology industry. Biotechnology is number 82 out of 148 industries.

Overall Score - 40
HALO has an Overall Score of 40. Find out what this means to you and get the rest of the rankings on HALO!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Halozyme Therapeutics, Inc. Stock Today?

Halozyme Therapeutics, Inc. (HALO) stock is trading at $39.77 as of 2:59 PM on Monday, Oct 4, a loss of -$0.98, or -2.4% from the previous closing price of $40.75. The stock has traded between $39.61 and $41.20 so far today. Volume today is below average. So far 396,140 shares have traded compared to average volume of 775,551 shares. Click Here to get the full Stock Report for Halozyme Therapeutics, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App